Baycox Bovis 50mg/ml oral suspension

البلد: أيرلندا

اللغة: الإنجليزية

المصدر: HPRA (Health Products Regulatory Authority)

اشتر الآن

تأكيد الحساب خصائص المنتج (SPC)
12-06-2017

العنصر النشط:

Toltrazuril

متاح من:

Bayer Limited

ATC رمز:

QP51AJ01

INN (الاسم الدولي):

Toltrazuril

جرعة:

50 milligram(s)/millilitre

الشكل الصيدلاني:

Oral suspension

نوع الوصفة الطبية :

POM: Prescription Only Medicine as defined in relevant national legislation

المجموعة العلاجية:

Cattle

المجال العلاجي:

toltrazuril

الخصائص العلاجية:

Coccidiostats

الوضع إذن:

Authorised

تاريخ الترخيص:

2006-01-25

خصائص المنتج

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Baycox Bovis 50mg/ml oral suspension.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Oral suspension.
White or yellowish suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle (calves on dairy farms).
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the prevention of clinical signs of coccidiosis and reduction of
coccidia shedding in housed calves replacing cows
producing milk for human consumption (dairy cows) on farms with a
confirmed history of coccidiosis caused by
_Eimeria bovis_ or_ Eimeria zuernii_.
4.3 CONTRAINDICATIONS
For environmental reasons:
Do not use in calves weighing more than 80 kg bodyweight.
Do not use in fattening units such as veal or beef calves.
For more details see sections 4.5, other precautions and section 5,
environmental properties.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
As with any antiparasiticide frequent and repeated use of
antiprotozoals from the same class may lead to the
development of resistance.
It is recommended to treat all calves in a pen
Hygienic measures may reduce the risk of bovine coccidiosis. It is
therefore, recommended to improve concomitantly
the hygienic conditions in the concerned facility, particularly
dryness and cleanliness.
To obtain maximum benefit, animals should be treated before the
expected onset of clinical signs, i.e. in the prepatent
period.
To alter the course of an established clinical coccidial infection, in
individual animals already showing signs of
diarrhoea, additional supportive therapy may be required.
1 ml contains:
ACTIVE SUBSTANCE:
Toltrazuril
50.0 mg
EXCIPIENT(S):
Sodium benzoate (E211)
2.1
mg
Sodium propionate (E281)
2.1
mg
For a full list of excipients, see section 6.1.
I
R
I
S
H
M
E
D
I
C
I
N
E
S
B
O
A
R
D
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___

                                
                                اقرأ الوثيقة كاملة
                                
                            

تنبيهات البحث المتعلقة بهذا المنتج